Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeting E2F1-DNA complexes with microgonotropen DNA binding agents

S Y Chiang1, T C Bruice, J C Azizkhan

  • 1Experimental Therapeutics Department, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.

Proceedings of the National Academy of Sciences of the United States of America
|April 1, 1997
PubMed
Summary

Microgonotropen (MGT) drugs effectively inhibit E2 factor 1 (E2F1) DNA binding. MGT-6a shows superior potency, highlighting MGTs as promising therapeutic agents for E2F1-related conditions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Subchoroidal Release of VEGF and bFGF Produces Choroidal Neovascularization in Rabbit.

Current eye research·2016
Same author

Efficient high-power terahertz beating in a dual-wavelength synchronously mode-locked laser with dual gain media.

Optics letters·2014
Same author

Photoluminescence properties of non-tapered InN nanorods grown by plasma-assisted metalorganic chemical vapor phase deposition.

Journal of nanoscience and nanotechnology·2010
Same author

Epidemiological and genetic studies of myotonic dystrophy type 1 in Taiwan.

Neuroepidemiology·2003
Same author

Effect of Rhizoma Corydalis on focal cerebral infarct in ischemia-reperfusion injured rats.

Acta pharmacologica Sinica·2001
Same author

The use of antibody D8/17 to identify B cells in adults with obsessive-compulsive disorder.

Psychiatry research·2001

Area of Science:

  • Medicinal Chemistry
  • Molecular Biology
  • Drug Discovery

Background:

  • Microgonotropen (MGT) are novel DNA-binding agents.
  • They feature a tripyrrole peptide for minor groove binding and polyamine chains for major groove interaction.
  • E2 factor 1 (E2F1) is a critical transcription factor involved in cell cycle regulation.

Purpose of the Study:

  • To evaluate the efficacy of MGTs as inhibitors of E2F1 association with its DNA promoter.
  • To compare the potency of MGTs with established DNA-binding drugs like distamycin.
  • To establish a structure-activity relationship between MGT binding affinity and E2F1 inhibition.

Main Methods:

  • Synthesis and characterization of MGT compounds.
  • DNA binding assays to determine equilibrium constants for MGTs with A+T-rich DNA sequences.

Related Experiment Videos

  • Electrophoretic mobility shift assays (EMSAs) to measure inhibition of E2F1-DNA complex formation.

    • Main Results:

    • MGTs demonstrated extraordinary effectiveness in inhibiting E2F1-DNA complex formation.
    • MGT-6a exhibited a 1000-fold greater potency than distamycin, with 50% inhibition at 0.00085 microM.
    • A direct correlation was observed between MGT equilibrium binding constants and their inhibitory activity against E2F1-DNA complex formation.

    Conclusions:

    • MGTs are highly potent inhibitors of E2F1-DNA interactions.
    • The drug design effectively targets both DNA grooves, enhancing inhibitory efficacy.
    • MGTs represent a promising class of compounds for therapeutic interventions targeting E2F1-mediated processes.